| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$6 |
Hydrix raises $3.89m under Institutional Entitlement Offer
|
20 May 2026 9:22AM |
$0.013 |
$0.004 |
fallen by
69.23%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix Limited completed the institutional component of its $8.183 million pro-rata accelerated renounceable entitlement offer.
- The Institutional Entitlement Offer raised approximately $3.89 million at an offer price of $0.005 per share.
- Institutional shareholders did not take up their entitlements, which were sold in the institutional shortfall bookbuild process.
- New institutional investors and family offices subscribed for all available shares under the bookbuild, raising $3,887,349 before offer costs.
- Hydrix's shares are expected to resume normal trading on the ASX on an ex-entitlement basis.
- The Retail Entitlement Offer aims to raise an additional $4.3 million, allowing eligible retail shareholders to subscribe for new shares at the same offer price.
- The proceeds will be used to retire and pay down debt, cover offer costs, and provide working capital for ongoing operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Iceni Gold Limited (ICL) ORDINARY FULLY PAID |
Materials |
$9 |
Exploration Update - Advancing Multiple Targets
|
20 May 2026 9:22AM |
$0.022 |
$0.024 |
risen by
9.09%
|
|
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$28 |
Noxopharms Sofra assets to be presented at global conference
|
20 May 2026 9:21AM |
$0.064 |
$0.092 |
risen by
43.75%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- Noxopharm’s Sofra assets will be presented at a global conference.
- The presentation will be by CSL at the Options for the Control of Influenza XIII Conference.
- Focus on improving delivery of self-amplifying mRNA vaccines.
- Sofra is a novel class of drugs targeting immune-related diseases.
- Potential applications include rheumatoid arthritis, lupus, diabetes, and oncology.
- Sofra’s versatility and immune system understanding are attracting industry attention.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Simble Solutions Limited (SIS) ORDINARY FULLY PAID |
Information Technology |
$16 |
Director Appointment
|
20 May 2026 9:21AM |
$0.006 |
$0.007 |
risen by
16.67%
|
|
| ImExHS Limited (IME) ORDINARY FULLY PAID |
Health Care |
$17 |
AGM - Chairman and CEO Addresses and Presentation
|
20 May 2026 9:20AM |
$0.350 |
$0.320 |
fallen by
8.57%
|
|
IME - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of $29 million for FY25, up 10% year-on-year.
- Underlying EBITDA of $1.6 million, meeting the top end of guidance.
- Development of Aquila+, an AI platform automating the full radiology workflow.
- Appointment of new CTO and Sales Director to strengthen leadership.
- Continued expansion into the Mexican market, supported by channel partners.
- Approval of CEO option grants and additional share placement capacities.
- Positive outlook for FY26 with expectations to exceed FY25 EBITDA.
- Focus on market expansion, technology development, and financial discipline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Many Peaks Minerals Limited (MPK) ORDINARY FULLY PAID |
Materials |
$133 |
Trading Halt
|
20 May 2026 9:19AM |
$0.930 |
$0.800 |
fallen by
13.98%
|
|
MPK - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Many Peaks Minerals Limited (MPK).
- The halt is pending an announcement regarding a proposed capital raising.
- Trading halt to remain in place until 22 May 2026 or upon the announcement release.
- Request made under ASX Listing Rule 17.1.
- The company is managing its continuous disclosure obligations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EBR Systems Inc (EBR) CDI 10:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$173 |
Purchasing Agreement Secured with CHRISTUS Health
|
20 May 2026 9:19AM |
$0.505 |
$0.385 |
fallen by
23.76%
|
|
EBR - Price-sensitive ASX Announcement
Full Release
Key Points
- EBR secured a three-year purchasing agreement with CHRISTUS Health.
- CHRISTUS Health is the ninth-largest hospital network in the U.S.
- The agreement covers the WiSE CRT System across 66 hospitals.
- The deal supports EBR's ongoing U.S. commercial rollout.
- CHRISTUS Health's network is primarily located in Texas, Louisiana, and New Mexico.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| KGL Resources Limited (KGL) ORDINARY FULLY PAID |
Materials |
$206 |
Corporate Presentation
|
20 May 2026 9:19AM |
$0.288 |
$0.268 |
fallen by
6.96%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$19 |
OncoSil Medical Receives TGA Approval in Australia
|
20 May 2026 9:17AM |
$0.390 |
$0.620 |
risen by
58.97%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- TGA approval received for OncoSil™ device for pancreatic cancer treatment in Australia.
- First Class III medical device approved targeting pancreatic tumors in Australia.
- Enables commercialization and broader market adoption in Australia.
- Strengthens global commercialization strategy for OncoSil Medical.
- Provides a new treatment option for approximately 4,353 new pancreatic cancer patients annually in Australia.
- Highlights Australia's leadership in oncology innovation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GenusPlus Group Ltd (GNP) ORDINARY FULLY PAID |
Industrials |
$2,170 |
Proposed issue of securities - GNP
|
20 May 2026 9:16AM |
$9.740 |
$10.680 |
risen by
9.65%
|
|
| Metgasco Limited (MEL) ORDINARY FULLY PAID |
Energy |
$1 |
Debt Bridging Facility
|
20 May 2026 9:16AM |
$0.016 |
$0.015 |
fallen by
6.25%
|
|
MEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Metgasco Limited accepts A$500,000 bridging loan facility.
- Loan provided by Glennon Small Companies Limited.
- Interest rate set at 10% per annum.
- Purpose is to meet short-term capital and working capital requirements.
- Restructuring of Metgasco's debt stack is a condition of the loan.
- Announcement authorized by Metgasco's Board.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ion Video Ltd (IOV) ORDINARY FULLY PAID |
Information Technology |
$75 |
US Media Tech Leader Joins ION Advisory Board
|
20 May 2026 9:16AM |
$0.360 |
$0.565 |
risen by
56.94%
|
|
IOV - Price-sensitive ASX Announcement
Full Release
Key Points
- Kelli Richards joins ION Video's Advisory Board.
- The Advisory Board is non-governance and aims to support strategic guidance.
- Richards brings extensive industry experience from the tech and media sectors.
- Advisory Board will aid in the company's commercialization strategy.
- Richards to receive equity incentives as part of her role.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GenusPlus Group Ltd (GNP) ORDINARY FULLY PAID |
Industrials |
$2,170 |
A$200M Placement for Acquisition of MPC Kinetic
|
20 May 2026 9:16AM |
$9.740 |
$10.680 |
risen by
9.65%
|
|
GNP - Price-sensitive ASX Announcement
Full Release
Key Points
- A$200 million placement for MPC Kinetic acquisition
- Placement at A$9.25 per New Share
- 5.0% discount to last closing price
- Bell Potter and Euroz Hartleys as Joint Lead Managers
- Completion of acquisition expected by 1 July 2026
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GenusPlus Group Ltd (GNP) ORDINARY FULLY PAID |
Industrials |
$2,170 |
Presentation- Acquisition of MPC Kinetic and Capital Raising
|
20 May 2026 9:16AM |
$9.740 |
$10.680 |
risen by
9.65%
|
|
| Redcastle Resources Limited (RC1) ORDINARY FULLY PAID |
Materials |
$17 |
Proposed issue of securities - RC1
|
20 May 2026 9:15AM |
$0.145 |
$0.125 |
fallen by
13.79%
|
|
| Redcastle Resources Limited (RC1) ORDINARY FULLY PAID |
Materials |
$17 |
Placement to Raise A$2 million
|
20 May 2026 9:15AM |
$0.145 |
$0.125 |
fallen by
13.79%
|
|
RC1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Placement to raise A$2 million.
- 14,285,714 shares at A$0.14 per share.
- Funds to expedite exploration and development.
- New shares expected to be issued on 26 May 2026.
- Xcel Capital Pty Ltd acted as sole lead manager.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Heavy Rare Earths Limited (HRE) ORDINARY FULLY PAID |
Materials |
$4 |
Heritage Clearance Received for South Ridge Maiden Drilling
|
20 May 2026 9:15AM |
$0.026 |
$0.020 |
fallen by
23.08%
|
|
HRE - Price-sensitive ASX Announcement
Full Release
Key Points
- Heritage clearance received from Dieri Aboriginal Corporation.
- Planned 25-hole, 2,500m maiden drill program at South Ridge.
- Historic data shows high-grade tin intersections.
- Helicopter used for site access due to weather-impacted roads.
- Submitted environmental protection and rehabilitation program.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IPH Limited (IPH) ORDINARY FULLY PAID |
Industrials |
$989 |
Update - Notification of buy-back - IPH
|
20 May 2026 9:14AM |
$3.630 |
$3.860 |
risen by
6.34%
|
|
| Critica Limited (CRI) ORDINARY FULLY PAID |
Materials |
$56 |
Jupiter attracts MRIWA and Trailblazer Grant Funding
|
20 May 2026 9:14AM |
$0.023 |
$0.019 |
fallen by
19.57%
|
|
CRI - Price-sensitive ASX Announcement
Full Release
Key Points
- Critica Limited secured $300,000 in funding from MRIWA and RTCM Trailblazer.
- The funding will accelerate the Jupiter project's metallurgical program.
- Funding supports R&D into alternative mineral processing methods like bioleaching.
- Critica partners with Curtin and James Cook universities and CMCI CRC.
- The CMCI CRC has over $53 million in Australian Government funding.
- Critica has joined the Defense Industrial Base Consortium in the U.S.
- The company aims for non-dilutive funding and strategic support to advance Jupiter.
- Critica's CEO, Jacob Deysel, highlights the importance of non-dilutive funding.
- Critica continues to engage with industry and government for grants and support.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Whitehaven Coal Limited (WHC) ORDINARY FULLY PAID |
Energy |
$6,760 |
Update - Notification of buy-back - WHC
|
20 May 2026 9:13AM |
$8.150 |
$8.220 |
risen by
0.86%
|
|
| Nyrada Inc (NYR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$106 |
Xolatryp Enhances Anthracycline Anti-Tumour Efficacy
|
20 May 2026 9:13AM |
$0.555 |
$0.430 |
fallen by
22.52%
|
|
NYR - Price-sensitive ASX Announcement
Full Release
Key Points
- Xolatryp enhances doxorubicin's anti-tumor effect in liver cancer models.
- Xolatryp shows anti-tumor activity both as monotherapy and in combination.
- The combination reduced tumor volume by 57% compared to control at Day 14.
- Xolatryp's monotherapy resulted in a 32% reduction in tumor volume.
- Future studies aim to optimize dosing strategies for better efficacy.
- Potential for Xolatryp to improve outcomes in anthracycline-treated cancer.
- Provisional patent application lodged for Xolatryp as an anti-cancer agent.
- Nyrada focuses on TRPC ion channel inhibitors for multiple medical conditions.
- Nyrada continues to evaluate Xolatryp across various tumor types.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Maronan Metals Limited (MMA) ORDINARY FULLY PAID |
Materials |
$141 |
Proposed issue of securities - MMA
|
20 May 2026 9:13AM |
$0.315 |
$0.450 |
risen by
42.86%
|
|
| Maronan Metals Limited (MMA) ORDINARY FULLY PAID |
Materials |
$141 |
$22 Million Strategic Investment by Kinterra Capital
|
20 May 2026 9:13AM |
$0.315 |
$0.450 |
risen by
42.86%
|
|
MMA - Price-sensitive ASX Announcement
Full Release
Key Points
- Maronan Metals Limited receives $22 million strategic investment from Kinterra Capital.
- Kinterra becomes a 19.99% shareholder.
- Investment supports expanded 2026 drilling program and feasibility study.
- Maronan's cash position increases to $36.6 million.
- Kinterra can nominate a director to Maronan's board.
- Agreement includes rights for Kinterra to participate in future equity issuances.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Webjet Group Limited (WJL) ORDINARY FULLY PAID |
Consumer Discretionary |
$163 |
Sustainability Report
|
20 May 2026 9:12AM |
$0.490 |
$0.415 |
fallen by
15.31%
|
|
| Webjet Group Limited (WJL) ORDINARY FULLY PAID |
Consumer Discretionary |
$163 |
Appendix 4G and Corporate Governance Statement
|
20 May 2026 9:12AM |
$0.490 |
$0.415 |
fallen by
15.31%
|
|
Call 1300 880 160
Start a chat
Schedule a call
